Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion

Katharina Schallmoser, Reinhard Henschler, Christian Gabriel, Mickey B.C. Koh, Thierry Burnouf

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Human platelet lysate (HPL), rich in growth factors, is an efficient alternative supplement to fetal bovine serum (FBS) for ex vivo propagation of stromal cell-based medicinal products. Since 2014, HPL has been a focus of the Working Party for Cellular Therapies of the International Society of Blood Transfusion (ISBT). Currently, as several Good Manufacturing Practice (GMP)-compliant manufacturing protocols exist, an international consensus defining the optimal modes of industrial production, product specification, pathogen safety, and release criteria of this ancillary material (AM) is needed. This opinion article by the ISBT Working Party summarizes the current knowledge on HPL production and proposes recommendations on manufacturing and quality management in line with current technological innovations and regulations of biological products and advanced therapy medicinal products.

Original languageEnglish
JournalTrends in Biotechnology
DOIs
Publication statusPublished - Jan 1 2019

    Fingerprint

Keywords

  • cell propagation
  • cell therapy
  • human platelet lysate
  • mesenchymal stromal cells

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering

Cite this